Alex Rivera-Toquica, Luis Eduardo Echeverría, Carlos Andrés Arias-Barrera, Fernán Mendoza-Beltrán, Diego Hernán Hoyos-Ballesteros, Carlos Andrés Plata-Mosquera, Juan Carlos Ortega-Madariaga, Juan Fernando Carvajal-Estupiñán, Viviana Quintero-Yepes, Luz Clemencia Zárate-Correa, Ángel Alberto García-Peña, Nelly Velásquez-López, Claudia Victoria Anchique, Clara Ines Saldarriaga, Juan Esteban Gómez-Mesa
INTRODUCTION: Although several guidelines recommend that patients with heart failure with reduced ejection fraction (HFrEF) be treated with angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARB) or angiotensin receptor - neprilysin inhibitors (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRA), and sodium-glucose cocotransporter-2 inhibitor (SGLT2i), there are still several gaps in their prescription and dosage in Colombia. This study aims to describe the use patterns of HFrEF treatments in the Colombian Heart Failure Registry (RECOLFACA)...
February 15, 2024: Cardiology